The 5-LO inhibitor, zileuton, has shown positive results in treating experimental models of colon, lung, and pancreatic cancers (Rioux and Castonguay, 1998; Wenger et al., 2002; Chen et al., 2004; Wculek and Malanchi, 2015). This evidence concerns the gene ALOX5 and pancreatic neoplasm.